Description: Sana Biotechnology, Inc. develops and delivers engineered cells as medicine for patients. It identifies and develops potential product candidates; and executes preclinical studies. The company develops technologies to repair and control genes in cells; and replace any cell in the body. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was founded in 2018 and is based in Seattle, Washington with additional offices in South San Francisco, California; and Cambridge, Massachusetts.
Home Page: www.sana.com
SANA Technical Analysis
188 East Blaine Street
Seattle,
WA
98102
United States
Phone:
206 701 7914
Officers
| Name | Title |
|---|---|
| Dr. Steven D. Harr M.D. | Pres, CEO & Director |
| Dr. Richard C. Mulligan Ph.D. | Exec. Vice Chairman & Head of SanaX |
| Mr. Nathan Hardy M.B.A. | Exec. VP & CFO |
| Dr. Sunil Agarwal M.D. | Exec. VP, Head of Devel. & Chief Medical Officer |
| Ms. Shanna Clouse Peek | Sr. VP & Head of Corp. Operations |
| Brittany Mccleery | Accounting Mang. |
| Dr. Edward Rebar Ph.D. | Sr. VP & CTO |
| Mr. Bernard J. Cassidy J.D. | Exec. VP & Gen. Counsel |
| Ms. Robin Andrulevich | Exec. VP & Chief People Officer |
| Mr. Paul Brunetta M.D. | Sr. VP and Head of Clinical & Translational Science |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3917 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 494 |